These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27772772)

  • 1. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
    J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
    Russo M; Calabrò RS; Naro A; Sessa E; Rifici C; D'Aleo G; Leo A; De Luca R; Quartarone A; Bramanti P
    Neural Plast; 2015; 2015():656582. PubMed ID: 25699191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
    Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
    Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 11. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
    BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Sastre-Garriga J; Vila C; Clissold S; Montalban X
    Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    Marinelli L; Mori L; Canneva S; Colombano F; Currà A; Fattapposta F; Bandini F; Capello E; Abbruzzese G; Trompetto C
    Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M; Vila C
    Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
    Lu L; Pearce H; Roome C; Shearer J; Lang IA; Stein K
    Pharmacoeconomics; 2012 Dec; 30(12):1157-71. PubMed ID: 23072659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.